Zyversa Therapeutics Inc. has announced it received a Minimum Bid Price Deficiency Letter from The Nasdaq Capital Market Stock Exchange on May 27, 2025. The notice indicates the company's common stock had a closing bid price below $1.00 for 30 consecutive business days, placing it in non-compliance with Listing Rule 5550(a)(2). Typically, companies have a 180-day period to regain compliance; however, Zyversa is not eligible for this due to two reverse stock splits within the past two years, including a 1-for-35 reverse split in December 2023 and a 1-for-10 reverse split in April 2024. Zyversa plans to appeal the decision and request a hearing before a panel, which will temporarily halt any suspension or delisting actions pending the panel's decision. The company must submit its appeal by June 3, 2025, to prevent its securities from being delisted on June 5, 2025. There is no guarantee that Zyversa will meet the necessary requirements for continued listing on the Nasdaq Capital Market.